Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Pairing Subjective Patient Rating and DBS Programming

Key facts

Where
München, GermanySee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 35 and 80 years old?

Source: NCT07336199, who can take part

Where in Germany

  • LMU University HospitalMünchen, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ludwig-Maximilians - University of Munich
Trial code
NCT07336199
Record updated
14 January 2026
Original description
This multicenter, prospective and retrospective diagnostic study investigates personalized programming strategies for deep brain stimulation (DBS) in patients with Parkinson's disease. DBS of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease; however, optimization of stimulation parameters remains time-consuming and resource-intensive due to the growing complexity of electrode designs and programming options.Read full original descriptionShow less

Pairing Subjective Patient Rating and Local Field Potentials for DBS Programming

This multicenter, prospective and retrospective diagnostic study investigates personalized programming strategies for deep brain stimulation (DBS) in patients with Parkinson's disease. DBS of the subthalamic nucleus (STN) is an established therapy for advanced Parkinson's disease; however, optimization of stimulation parameters remains time-consuming and resource-intensive due to the growing complexity of electrode designs and programming options.

The PERCEPT-DBS study aims to improve DBS programming by combining subjective patient-reported outcomes with objective electrophysiological biomarkers. Specifically, the study examines the relationship between patients' subjective assessment of stimulation efficacy, measured using a visual analogue scale (VAS), and local field potentials (LFPs), with a focus on beta-band activity recorded from implanted DBS electrodes. These data are integrated with structural and functional neuroimaging to identify individualized stimulation "sweet spots" within the STN.

A total of 24 patients with idiopathic Parkinson's disease treated with bilateral STN-DBS will be recruited across several German DBS centers. Participants undergo standardized clinical assessments, VAS-based blinded monopolar reviews, and LFP recordings using sensing-enabled implantable pulse generators. In addition, imaging-based analyses are performed to relate electrophysiological and subjective measures to anatomical and connectomic features.

The primary objective is to determine whether electrophysiological markers correlate with subjective patient ratings and whether their overlap defines personalized optimal stimulation targets. By integrating patient perception with neurophysiological and imaging data, this study seeks to advance individualized DBS programming strategies and contribute to the development of more efficient, patient-centered, and potentially adaptive DBS therapies.

Inclusion: Age between 35 and 80 years; Clinically confirmed idiopathic Parkinson's disease according to Movement Disorder Society (MDS) criteria; Status post bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS); Implanted DBS system suitable for electrophysiological recordings (prospective cohort: sensing-enabled IPG); Ability to understand study procedures and communicate reliably with the investigator; Written informed consent provided.

Exclusion: Any condition impairing the ability to provide informed consent or comply with study procedures; Presence of exclusion criteria for Parkinson's disease according to MDS criteria; Manifest dementia according to ICD-10 criteria; Severe neurological, psychiatric, or medical conditions interfering with study participation or assessments.

ClinicalTrials.gov NCT07336199